Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


14.05.2018

1 Ann Surg Oncol
3 BMC Cancer
1 Br J Dermatol
1 Clin Exp Metastasis
1 J Invest Dermatol
7 Lancet Oncol
6 Melanoma Res
1 Oncol Rep


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Surg Oncol

  1. CUI C, Lian B, Zhou L, Song X, et al
    Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients.
    Ann Surg Oncol. 2018 May 10. pii: 10.1245/s10434-018-6503.
    PubMed     Text format     Abstract available


    BMC Cancer

  2. SI L, Zhang X, Xu Z, Jiang Q, et al
    Vemurafenib in Chinese patients with BRAF(V600) mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.
    BMC Cancer. 2018;18:520.
    PubMed     Text format     Abstract available

  3. MCDONALD MA, Sanghvi P, Bykowski J, Daniels GA, et al
    Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
    BMC Cancer. 2018;18:549.
    PubMed     Text format     Abstract available

  4. GUIDA M, Tommasi S, Strippoli S, Natalicchio MI, et al
    The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
    BMC Cancer. 2018;18:552.
    PubMed     Text format     Abstract available


    Br J Dermatol

  5. FUJISAWA Y
    Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors: reply from the authors.
    Br J Dermatol. 2018 May 7. doi: 10.1111/bjd.16689.
    PubMed     Text format    


    Clin Exp Metastasis

  6. WEITMAN ES, Zager JS
    Regional therapies for locoregionally advanced and unresectable melanoma.
    Clin Exp Metastasis. 2018 May 8. pii: 10.1007/s10585-018-9890.
    PubMed     Text format     Abstract available


    J Invest Dermatol

  7. OLSEN CM, Pandeya N, Thompson BS, Dusingize JC, et al
    Physician skin checks before the diagnosis of melanoma correlate with tumor characteristics.
    J Invest Dermatol. 2018 May 4. pii: S0022-202X(18)31952.
    PubMed     Text format    


    Lancet Oncol

  8. RIBAS A, Kirkwood JM, Flaherty KT
    Anti-PD-1 antibody treatment for melanoma.
    Lancet Oncol. 2018;19:e219.
    PubMed     Text format    

  9. NABI H, Guertin JR, Talbot D, Diorio C, et al
    Body-mass index and metastatic melanoma outcomes.
    Lancet Oncol. 2018;19:e226.
    PubMed     Text format    

  10. LENNON H, Badrick E, Sperrin M, Renehan AG, et al
    Body-mass index and metastatic melanoma outcomes.
    Lancet Oncol. 2018;19:e225.
    PubMed     Text format    

  11. MCQUADE JL, Daniel CR, Davies MA
    Body-mass index and metastatic melanoma outcomes - Authors' reply.
    Lancet Oncol. 2018;19:e227-e228.
    PubMed     Text format    

  12. BEAVER JA, Keegan P, Lemery S, Pazdur R, et al
    Anti-PD-1 antibody treatment for melanoma - Authors' reply.
    Lancet Oncol. 2018;19:e220.
    PubMed     Text format    

  13. WEN H, Guo T, Feng C
    Body-mass index and metastatic melanoma outcomes.
    Lancet Oncol. 2018;19:e223.
    PubMed     Text format    

  14. DALY LE, Ryan AM, Power DG
    Body-mass index and metastatic melanoma outcomes.
    Lancet Oncol. 2018;19:e224.
    PubMed     Text format    


    Melanoma Res

  15. AFZAL MZ, Shirai K
    Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000459.
    PubMed     Text format     Abstract available

  16. GONG HZ, Zheng HY, Li J
    The clinical significance of KIT mutations in melanoma: a meta-analysis.
    Melanoma Res. 2018 May 9. doi: 10.1097/CMR.0000000000000454.
    PubMed     Text format     Abstract available

  17. SCHOUWENBURG MG, Jochems A, Leeneman B, Franken MG, et al
    Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000453.
    PubMed     Text format     Abstract available

  18. ASCIERTO PA, Bastholt L, Ferrucci PF, Hansson J, et al
    The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000455.
    PubMed     Text format     Abstract available

  19. TENGDA L, Shuping L, Mingli G, Jie G, et al
    Serum exosomal microRNAs as potent circulating biomarkers for melanoma.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000450.
    PubMed     Text format     Abstract available

  20. MOSHE M, Levi A, Ad-El D, Ben-Amitai D, et al
    Malignant melanoma clinically mimicking pyogenic granuloma: comparison of clinical evaluation and histopathology.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000451.
    PubMed     Text format     Abstract available


    Oncol Rep

  21. RYABAYA O, Prokofieva A, Khochenkov D, Abramov I, et al
    Inhibition of endoplasmic reticulum stress-induced autophagy sensitizes melanoma cells to temozolomide treatment.
    Oncol Rep. 2018 May 9. doi: 10.3892/or.2018.6430.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: